Kenneth C. Cundy
2023 - Anebulo Pharmaceuticals
In 2023, Kenneth C. Cundy earned a total compensation of $495.6K as Chief Scientific Officer at Anebulo Pharmaceuticals, a 1% increase compared to previous year.
Compensation breakdown
| Bonus | $63,500 |
|---|---|
| Option Awards | $70,475 |
| Salary | $361,650 |
| Total | $495,625 |
Cundy received $361.7K in salary, accounting for 73% of the total pay in 2023.
Cundy also received $63.5K in bonus and $70.5K in option awards.
Rankings
In 2023, Kenneth C. Cundy's compensation ranked 2,045th out of 3,006 executives tracked by ExecPay. In other words, Cundy earned more than 32.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,045 out of 3,006 | 32nd |
Division Manufacturing | 1,163 out of 1,650 | 30th |
Major group Chemicals And Allied Products | 718 out of 918 | 22nd |
Industry group Drugs | 701 out of 881 | 20th |
Industry Pharmaceutical Preparations | 504 out of 637 | 21st |
Source: SEC filing on October 30, 2023.
Cundy's colleagues
We found three more compensation records of executives who worked with Kenneth C. Cundy at Anebulo Pharmaceuticals in 2023.
News
Anebulo Pharmaceuticals CEO Simon Allen's 2023 pay falls 63% to $778K
October 30, 2023
Anebulo Pharmaceuticals CEO Simon Allen receives $2.1M in 2022
October 17, 2022
CohBar CEO Joseph Sarret receives $3.2M in 2021
April 22, 2022
CohBar CEO Steven Engle receives $2.4M in 2019
April 29, 2020
CohBar CEO Philippe Calais receives $1.6M in 2018
April 24, 2019